On the other hand, the interaction between TIGIT and CD226 attenuates immune operations, while nectin-2 and nectin-4 are identified as promising targets in cancer treatment due to their effects on the behavior of tumor cells (14, 15). The gene discussed is CD226; the disease is neoplasm.